Open

Coming up

Don't miss

Replay


LATEST SHOWS

INSIDE THE AMERICAS

US strategy to combat the Islamic State group

Read more

AFRICA NEWS

Nigeria attack: Bomb blast in college in Kano

Read more

IN THE PAPERS

'It's No Go' as Scotland rejects independence

Read more

MEDIAWATCH

Scotland's relationship status: 'It's complicated'

Read more

DEBATE

Scotland Referendum: Will They Stay or Will They Go?

Read more

DEBATE

Hollande Press Conference: French President Tackles Record Unpopularity

Read more

FOCUS

Cleaning up Thailand's shady surrogacy industry

Read more

ENCORE!

The Biennale des Antiquaires: Where Miro meets million-dollar jewellery and antiques

Read more

THE OBSERVERS

Attacks on migrants in Tangiers and unwelcome stares from men in Cairo

Read more

Cancer drug may help avert transplant rejection

Latest update : 2008-12-27

The bortezomib, a cancer treatment drug, has been tested successfully on several patients whose bodies had been rejecting transplanted organs, an American study found, concluding to "significant implications for transplantation."

AFP - A drug used to treat cancer has proven effective at stopping the body from rejecting a transplanted organ when other treatments failed, a study published Saturday found.
  
US researchers administered the drug, bortezomib, to six patients whose immune systems were attacking transplanted kidneys and who did not respond to traditional anti-rejection treatments.
  
In each case, the drug promptly reversed the rejection, improved organ function, provided prolonged reductions in antibody levels and suppressed recurrent rejection for at least five months.
  
"This has significant implications for transplantation and auto immune disease," said study co-author Steve Woodle, chief of transplant surgery at the University of Cincinnati in Ohio.
  
Woodle's team is currently conducting four clinical trials to expand upon these preliminary findings.
  
The drug's side effects proved to be both predictable and manageable and toxicity levels were much less than those associated with other anti-cancer agents, the study found.
  
"We are pleased to see its toxicities are similar in transplant recipients suffering from treatment-resistant mixed organ rejection," said study co-author Jason Everly, an oncology pharmacist at the University of Cincinnati.
  
"We hope it will be a viable therapeutic treatment option in this patient group."
  
Previous studies had found that B-cells play a large role in organ rejection by making immune proteins that attack transplants.
  
The drug targets these antibody-producing plasma cells and had been shown to suppress transplant rejection in the laboratory before Woodle and his team tested it on patients.
  
The study was published in the journal Transplantation.

Date created : 2008-12-27

COMMENT(S)